| Convergent antibody responses to SARS-CoV-2 in convalescent individuals DF Robbiani, C Gaebler, F Muecksch, JCC Lorenzi, Z Wang, A Cho, ... Nature 584 (7821), 437-442, 2020 | 2237 | 2020 |
| Evolution of antibody immunity to SARS-CoV-2 C Gaebler, Z Wang, JCC Lorenzi, F Muecksch, S Finkin, M Tokuyama, ... Nature 591 (7851), 639-644, 2021 | 1977 | 2021 |
| Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Y Weisblum, F Schmidt, F Zhang, J DaSilva, D Poston, JCC Lorenzi, ... elife 9, e61312, 2020 | 1610 | 2020 |
| Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 M Caskey, F Klein, JCC Lorenzi, MS Seaman, AP West Jr, N Buckley, ... Nature 522 (7557), 487-491, 2015 | 910 | 2015 |
| Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies CO Barnes, AP West, KE Huey-Tubman, MAG Hoffmann, NG Sharaf, ... Cell 182 (4), 828-842. e16, 2020 | 884 | 2020 |
| Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses F Schmidt, Y Weisblum, F Muecksch, HH Hoffmann, E Michailidis, ... Journal of Experimental Medicine 217 (11), e20201181, 2020 | 660 | 2020 |
| Combination therapy with anti-HIV-1 antibodies maintains viral suppression P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler, K Millard, ... Nature 561 (7724), 479-484, 2018 | 587 | 2018 |
| HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption JF Scheid, JA Horwitz, Y Bar-On, EF Kreider, CL Lu, JCC Lorenzi, ... Nature 535 (7613), 556-560, 2016 | 562 | 2016 |
| Enhanced SARS-CoV-2 neutralization by dimeric IgA Z Wang, JCC Lorenzi, F Muecksch, S Finkin, C Viant, C Gaebler, ... Science translational medicine 13 (577), eabf1555, 2021 | 530 | 2021 |
| HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 T Schoofs, F Klein, M Braunschweig, EF Kreider, A Feldmann, L Nogueira, ... Science 352 (6288), 997-1001, 2016 | 393 | 2016 |
| Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques M Shingai, OK Donau, RJ Plishka, A Buckler-White, JR Mascola, ... Journal of Experimental Medicine 211 (10), 2061-2074, 2014 | 392 | 2014 |
| Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo A Schäfer, F Muecksch, JCC Lorenzi, SR Leist, M Cipolla, S Bournazos, ... Journal of Experimental Medicine 218 (3), e20201993, 2020 | 363 | 2020 |
| Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients F Muecksch, H Wise, B Batchelor, M Squires, E Semple, C Richardson, ... The Journal of infectious diseases 223 (3), 389-398, 2021 | 300 | 2021 |
| Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations F Muecksch, Y Weisblum, CO Barnes, F Schmidt, D Schaefer-Babajew, ... Immunity 54 (8), 1853-1868. e7, 2021 | 294 | 2021 |
| Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants J Xu, K Xu, S Jung, A Conte, J Lieberman, F Muecksch, JCC Lorenzi, ... Nature 595 (7866), 278-282, 2021 | 244 | 2021 |
| Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA JCC Lorenzi, YZ Cohen, LB Cohn, EF Kreider, JP Barton, GH Learn, ... Proceedings of the National Academy of Sciences 113 (49), E7908-E7916, 2016 | 218 | 2016 |
| Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis J Lorenzi, A Trombone, C Rocha, L Almeida, R Lousada, T Malardo, ... BMC biotechnology 10 (1), 77, 2010 | 210 | 2010 |
| Planejamento, montagem e aplicação de modelos didáticos para abordagem de biologia celular e molecular no ensino médio por graduandos de ciências biológicas TC Orlando, AR Lima, AM da Silva, CN Fuzissaki, CL Ramos, D Machado, ... Revista de Ensino de Bioquímica 7 (1), 1-17, 2009 | 202 | 2009 |
| Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller Science Translational Medicine 9 (373), eaal2144, 2017 | 195 | 2017 |
| Non-neutralizing antibodies alter the course of HIV-1 infection in vivo JA Horwitz, Y Bar-On, CL Lu, D Fera, AAK Lockhart, JCC Lorenzi, ... Cell 170 (4), 637-648. e10, 2017 | 192 | 2017 |
michel nussenzweigHHMI, The Rockefeller UniversityVerified email at rockefeller.edu
